A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

  • STATUS
    Recruiting
  • End date
    Jun 3, 2024
  • participants needed
    600
  • sponsor
    Nektar Therapeutics
Updated on 1 August 2021
Investigator
Nektar Recruitment
Primary Contact
Investigator Site - Rosario (0.0 mi away) Contact
+185 other location
tyrosine
sunitinib
systemic therapy
measurable disease
carcinoma
growth factor
karnofsky performance status
kinase inhibitor
metastasis
cabozantinib
brain metastases
vaccine therapy
pd-l1
brain metastasis
programmed cell death 1 ligand 1
nivolumab
curative surgery
metastatic renal cell carcinoma
advanced renal cell carcinoma

Summary

The main purpose of this study is to compare the objective response rate (ORR) and overall survival (OS) of bempegaldesleukin (NKTR-214: BEMPEG) combined with nivolumab to that of tyrosine kinase inhibitor (TKI) monotherapy (sunitinib or cabozantinib) in IMDC intermediateor poor-risk patients and IMDC all-risk patients with previously untreated advanced renal cell carcinoma (RCC).

Details
Condition Adenocarcinoma, Malignant neoplasm of kidney, Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Kidney Cancer, Kidney Cancer, Malignant Adenoma, Renal Cell Cancer, Renal Cancer, clear cell renal cell carcinoma
Treatment Nivolumab, Sunitinib, Cabozantinib, NKTR-214, bempegaldesleukin
Clinical Study IdentifierNCT03729245
SponsorNektar Therapeutics
Last Modified on1 August 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note